NeuroPace Inc

NeuroPace reports 25% revenue growth in FY2025, with 2026 guidance projecting 20‑22% core RNS revenue growth and a strong market‑adoption outlook.

NeuroPace, Inc. faces financial challenges despite its innovative technology in treating neurological disorders, requiring the company to balance innovation with financial viability to achieve long-term success.

NeuroPace Inc. has achieved safety milestones with its RNS System, but a recent clinical trial fell short on efficacy, leaving the company at a crossroads with investors and stakeholders in a state of cautious optimism.

NeuroPace Inc. has reported a 24% increase in revenue for Q1 2025, driven by its expanding presence in the epilepsy treatment market.